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Dr Karl Illig (Rochester, NY). I am a big fan of this concept,
and congratulate you on pursuing this. Maybe everyone else in the
room is ahead of me, but I only became aware of this issue a few
years ago when patients started showing up unable to pursue
aggressive cardiac rehabilitation because they couldn’t walk. Your
analysis is great, but it is fairly mathematical. I now consider
inability to complete cardiac rehabilitation a pretty good indication
for aggressive revascularization. Do you share this bias?
Dr John V. White. I agree with you. I think that this is an
excellent indication for invasive intervention in the claudicant. We
needed to establish a database, which is why we undertook the
mathematical analysis. We are carefully following these patients
and we will report our clinical results in the future.
DrAnil Hingorani (Brooklyn, NY). I’d like to actually reflect
on those comments. I think we have a very active cardiac rehab
program andwe have had the same type of issues where patients are
not able to complete their cardiac rehab program because of their
claudication. I am concerned, though, in your Markov model you
only resulted in 41 lives per 10,000 patients who would benefit
from this? The number seems somewhat small in terms of you have
to do 10,000 patients to get 41 patients to benefit.
DrWhite.We were looking strictly at mortality. Our hypoth-
esis stated that if you cannot reduce patient mortality through
cardiac rehab and you did nothing, those patients remain at high
risk. So the initial passthrough of the Markov model, which is
indeed quite complex, was simply to look at overall mortality. As
we began to work with the model, looking at quality-adjusted
life-years, for example, there is a statistically significant benefit in
the selective treatment of claudicants. The comprehensive strategy
where all claudicants would be identified prior to entry into a
program, and treated, probably will never reach a statistical signif-
icance no matter how we vary the probability parameters.
DrHingorani.Andwhat was the cost per quality life per year?
Dr White. It is about $70,000.
Dr John Blebea (Philadelphia, Pa). It appears to me that you
are presenting an association and not necessarily a causal relation-
ship. Do these patients fail cardiac rehab because specifically of
limiting claudication, or was the ABI [ankle-brachial index] and
claudication simply a surrogate marker of more advanced disease?
You are also proposing a very aggressive interventional policy on
the assumption that mortality will subsequently be decreased.
However, if lower extremity occlusive disease is but a marker of
more severe systemic atherosclerotic disease, will doing a bypass inDr White. Those are two great questions, John. The answer
appears to be that if we allow these patients to successfully com-
plete their cardiac rehabilitation, then there will be a reduction in
mortality, at least as predicted by all the meta-analyses available on
cardiac rehabilitation.
As to your first question, there are a plethora of articles trying
to ascertain why patients don’t return for cardiac rehabilitation.
Claudication as sole cause has never been evaluated. Although ABI
and WIQ [Walking Impairment Questionnaire] scores do seem to
be indirect measures, a direct survey of patients yields no greater
information. Therefore, because the walking impairment question-
naire has such great statistical correlation with walking distance and
other outcomes, we used that as our major parameter for ascertain-
ing the presence of peripheral arterial disease and symptoms of
intermittent claudication.
Dr Marc Mitchell (Jackson, Miss). I enjoyed your presenta-
tion and have a comment. This situation is not just limited to
patients with cardiac disease. We now have a handful of patients
that underwent joint replacement surgery and were unable to
rehabilitate because of vascular disease. Once we treated their
peripheral arterial disease, they were able to go on with their
orthopedic rehabilitation. This problem is probably more wide-
spread than we really think.
Dr White. Thank you for those comments and I completely
agree.
DrGeorge Andros (Van Nuys, Calif). As surgeons, we think of
interventions in terms of endovascular and open; but a supervised
walking program is an intervention as well. What you are asking these
people to do is to walk for their hearts instead of their legs. It has been
well documented that supervised walking programs ameliorate clau-
dication symptoms as well as increase walking distance and ABIs. If
patients don’t experience cardiac symptoms before the vascular clau-
dication symptoms occur during exercise, what is the harm in having
the patient undertake a peripheral arterial walking programfirst? If the
legs don’t improve enough, both subjectively andobjectively, to allow
sufficient cardiac exercise with its accrued benefits then you can always
proceed with leg revascularization. Bear in mind, however, as the
Oxford University group showed many years ago, endoluminal ther-
apy may not be as durable in achieving sustained improvements in
claudication as a walking program. You might be back where you
started.
Dr White. That is a very insightful observation. We did look
at, for the purposes of the Markov model, a combined cardiac and
vascular rehabilitation program, which clearly dominates all other
strategies.
